

CLAIMS

1. Specific therapeutic immunomodulatory complex, **characterized in that it** comprises:

- dual molecules constituted by the coupling of a functional amino acid arm, ensuring binding to a target, with a genetic RNA arm corresponding to the coded description of the composition of the functional arm,
- bacterial membrane fractions glycopeptides and/or lipopolysaccharides,

10 *RNA - collagen group* the ribonucleic acids (RNA) being of ribosomal origin and extracted from strains chosen from the following group: *Helicobacter pylori, hepaticus, coronari, Campylobacter* or from a mixture thereof.

15 2. Immunomodulatory complex according to Claim 1, **characterized in that** the amino acids are amino acids from collagen.

3. Immunomodulatory complex according to Claim 2, **characterized in that** the amino acids from collagen are chosen from the following group: aspartic acid, 20 hydroxyproline, threonine, serine, glutamic acid, proline, glycine, alanine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, lysine, histidine, arginine, or a mixture thereof.

4. Immunomodulatory complex according to one of 25 Claims 1 to 3, for its use in the treatment of diseases caused by *Helicobacter* bacteria, by the production of antibodies and the production of endogenous interferon.

5. Immunomodulatory complex according to one of

Claims 1 to 3, for its use as an anti-idiotype vaccine against the idiotypes of anti-bacterial antibodies which make it possible to avoid, in particular, recidivations of the initial digestive tract pathology.

5 6. Immunomodulatory complex according to one of Claims 1 to 3, for its use against bacterial resistance to conventional antibiotic treatments and the like.

7. Anti-Helicobacter-specific immunomodulatory and vaccine complex according to one of the preceding claims,

10 10 **characterized** *B* in that it is presented in a packaging allowing the simultaneous administration of major anti-inflammatory agents of the corticoid type, of antibiotics, of antisecretory agents, (proton pump inhibitors, of the type including Omeprazole or anti-H₂, and the like) or other products with bacteriostatic, bactericidal or bacteriolytic effects, for eradicating Helicobacter generating pathogeneses by factors linked to the bacterium (production of various cytotoxins, of inflammation mediators: Interleukin I, tumour necrosis factor alpha), or by factors linked to the host.

15 15 **characterized** *B* in that it is presented in a packaging allowing the simultaneous administration of major anti-inflammatory agents of the corticoid type, of antibiotics, of antisecretory agents, (proton pump inhibitors, of the type including Omeprazole or anti-H₂, and the like) or other products with bacteriostatic, bactericidal or bacteriolytic effects, for eradicating Helicobacter generating pathogeneses by factors linked to the bacterium (production of various cytotoxins, of inflammation mediators: Interleukin I, tumour necrosis factor alpha), or by factors linked to the host.

20 20 **characterized** *B* in that it is presented in a packaging allowing the simultaneous administration of major anti-inflammatory agents of the corticoid type, of antibiotics, of antisecretory agents, (proton pump inhibitors, of the type including Omeprazole or anti-H₂, and the like) or other products with bacteriostatic, bactericidal or bacteriolytic effects, for eradicating Helicobacter generating pathogeneses by factors linked to the bacterium (production of various cytotoxins, of inflammation mediators: Interleukin I, tumour necrosis factor alpha), or by factors linked to the host.

25 25 **characterized** *B* in that it is presented in a packaging allowing the simultaneous administration of major anti-inflammatory agents of the corticoid type, of antibiotics, of antisecretory agents, (proton pump inhibitors, of the type including Omeprazole or anti-H₂, and the like) or other products with bacteriostatic, bactericidal or bacteriolytic effects, for eradicating Helicobacter generating pathogeneses by factors linked to the bacterium (production of various cytotoxins, of inflammation mediators: Interleukin I, tumour necrosis factor alpha), or by factors linked to the host.

claim 7

a 8. Immunomodulatory complex according to the preceding claim, **characterized** by a packaging in the form such that it can be administered by various routes: infusions, intravenous injections, subcutaneous injections, transdermal devices, or per os.

Add B^a

Add B'
(abstract)